SA
LENZ

Scarborough Advisors’s LENZ Therapeutics LENZ Stock Holding History

Scarborough Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$732 Buy
+80
New +$1.12K ﹤0.01% 657

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Scarborough Advisors's LENZ Position: Q1 2026 in Review

Scarborough Advisors opened a new position in LENZ Therapeutics (LENZ) in Q1 2026: 80 shares worth $732. The stake represents ﹤0.01% of the portfolio and ranks #657 among its holdings.

145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Scarborough Advisors held 80 shares of LENZ Therapeutics worth $732 as of Q1 2026.
  • LENZ Therapeutics was a new Scarborough Advisors position in Q1 2026.
  • LENZ Therapeutics made up ﹤0.01% of Scarborough Advisors's portfolio in Q1 2026, its #657 holding.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Scarborough Advisors's 13F filing for Q1 2026, filed 7 May 2026.